文献速递膀胱癌与上尿路尿路上皮癌

肿瘤浸润免疫细胞预测非肌层浸润性膀胱癌膀胱内BCG治疗反应的价值:系统综述与荟萃分析

Value of tumour-infiltrating immune cells in predicting response to intravesical BCG in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis.
PubMed 文献 · BJU Int · 2020-11-09

该系统综述与荟萃分析纳入15项研究共791例接受膀胱内BCG治疗的非肌层浸润性膀胱癌患者,评估肿瘤浸润免疫细胞对肿瘤学结局及BCG治疗反应的预测价值。10项研究报告肿瘤浸润免疫细胞是肿瘤学结局和BCG治疗反应的显著预测因素。肿瘤相关巨噬细胞与更差的无复发生存期相关(合并风险比2.30,95%CI 1.64-3.22)。

要点

  • 肿瘤浸润免疫细胞是非肌层浸润性膀胱癌患者无复发生存期和BCG治疗反应的显著预测因素。
  • 肿瘤相关巨噬细胞与更差的无复发生存期相关(合并HR 2.30,95%CI 1.64-3.22)。
  • 将肿瘤浸润免疫细胞纳入风险分层模型可能有助于临床决策。

核心结论

  • 肿瘤浸润免疫细胞是非肌层浸润性膀胱癌患者无复发生存期和BCG治疗反应的显著预测因素。
  • 将肿瘤浸润免疫细胞纳入风险分层模型可能帮助患者和医生在临床决策中最大化BCG治疗获益。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Scopus和Cochrane Library(2020年7月),遵循PRISMA声明。
  • 纳入15项研究,共791例接受膀胱内BCG治疗的非肌层浸润性膀胱癌患者。
  • 采用固定效应模型计算合并无复发生存率。

主要发现

  • 10项研究报告肿瘤浸润免疫细胞是肿瘤学结局和BCG治疗反应的显著预测因素。
  • 肿瘤相关巨噬细胞与更差的无复发生存期相关(合并风险比2.30,95%CI 1.64-3.22)。

临床怎么用

  • 肿瘤浸润免疫细胞可用于预测非肌层浸润性膀胱癌患者对BCG治疗的反应和无复发生存期。
  • 考虑将肿瘤浸润免疫细胞纳入风险分层模型以辅助临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the predictive value of tumour-infiltrating immune cells (TIICs) on oncological outcomes and response to BCG treatment in patients with non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: A systematic review and meta-analysis was performed using PubMed, Scopus and the Cochrane Library in July 2020 to identify relevant studies according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The pooled recurrence-free survival (RFS) rate was calculated using a fixed-effect model. RESULTS: We retrieved 15 studies (including 791 patients) evaluating the effect of TIICs on oncological outcomes in patients with NMIBC treated with intravesical BCG. TIICs were reported to be a significant predictor of oncological outcomes and response to BCG treatment in 10 studies. Tumour-associated macrophages were associated with worse RFS (pooled hazard ratio 2.30, 95% confidence interval 1.64-3.22). CONCLUSIONS: Based on these data, TIICs are significant predictors of RFS and response to BCG treatment in patients with NMIBC; therefore, incorporation of TIICs into risk stratification models may help patients and physicians in the clinical decision-making process in order to achieve the maximum possible benefit from BCG treatment.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Kardoust Parizi M, Shariat SF, Margulis V, et al. Value of tumour-infiltrating immune cells in predicting response to intravesical BCG in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis. BJU Int. 2020. PMID: 33073457. doi:10.1111/bju.15276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。